UCB (OTCMKTS:UCBJF) Reaches New 12-Month High – Time to Buy?

Shares of UCB SA (OTCMKTS:UCBJF) hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $317.94 and last traded at $317.94, with a volume of 186 shares. The stock had previously closed at $302.5125.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on UCBJF. Stephens reissued an “overweight” rating on shares of UCB in a report on Thursday. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of UCB in a research report on Monday, December 8th. Finally, Barclays reaffirmed an “overweight” rating on shares of UCB in a research note on Tuesday, January 6th. Four analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy”.

UCB Stock Performance

The firm’s 50-day moving average is $283.06 and its 200 day moving average is $257.17. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.